TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 10778915

Group type: EXPERIMENTAL
Intervention: Inhaled corticosteroids (IHC) for 8 weeks
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: N‐acetylcysteine (NAC) for 8 weeks
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Long-term treatment with NAC
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Long-term treatment with IHC
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Sputum from COPD patients before treatment with IHC
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Sputum from COPD patients before treatment with NAC
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Basal adhesion of unstimulated PMNs
Number of subjects: 20
Study: 9489047

Group type: EXPERIMENTAL
Intervention: Therapeutic community (TC)
Number of subjects: 694

Group type: COMPARATOR
Intervention: Community residence (CR)
Number of subjects: 694

Group type: EXPERIMENTAL
Intervention: Overall attrition rates
Number of subjects: 694
Study: 8406147

Group type: EXPERIMENTAL
Intervention: Omeprazole (20 mg twice daily) and amoxicillin suspension (500 mg four times daily) for two weeks
Number of subjects: 40

Group type: COMPARATOR
Intervention: Bismuth subsalicylate (600 mg three times daily), metronidazole (400 mg three times daily), tetracycline (500 mg three times daily), and ranitidine (300 mg in the evening) for two weeks
Number of subjects: 40
Study: 3332119

Group type: EXPERIMENTAL
Intervention: Cyclosporin (CSA)
Number of subjects: 59

Group type: COMPARATOR
Intervention: Methotrexate (MTX)
Number of subjects: 59
Study: 31236732

Group type: EXPERIMENTAL
Intervention: Providers with high indegree centrality
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Influence of providers
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Interviews
Number of subjects: 0
Study: 29306057

Group type: EXPERIMENTAL
Intervention: Omega-3 and vitamin E co-supplementation (1000mg omega-3 fatty acids plus 400 IU vitamin E per day for 12 weeks)
Number of subjects: 40
Study: 27050082

Group type: EXPERIMENTAL
Intervention: Customized vestibular rehabilitation (VR)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Wait-listed control group (usual medical care)
Number of subjects: 40
Study: 24911979

Group type: EXPERIMENTAL
Intervention: Written emotional disclosure
Number of subjects: 78

Group type: COMPARATOR
Intervention: Control writing condition
Number of subjects: 78
Study: 22344742

Group type: EXPERIMENTAL
Intervention: Clonazepam (0.5 mg/day, n = 10)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo (lactose, n = 10)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Clonazepam (0.5 mg/day)
Number of subjects: 20
Study: 20210263

Group type: EXPERIMENTAL
Intervention: Generic medications
Number of subjects: 0

Group type: COMPARATOR
Intervention: Brand-name medications
Number of subjects: 0
Study: 18928121

Group type: EXPERIMENTAL
Intervention: Acupuncture at Shenmen (HT 7)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Acupuncture at Yanglao (SI 6)
Number of subjects: 12
Study: 15812554

Group type: EXPERIMENTAL
Intervention: Chemotherapy
Number of subjects: 875

Group type: EXPERIMENTAL
Intervention: Chemoradiation
Number of subjects: 875

Group type: COMPARATOR
Intervention: No treatment (Control)
Number of subjects: 875
Study: 12139873

Group type: EXPERIMENTAL
Intervention: Breast milk
Number of subjects: 37

Group type: COMPARATOR
Intervention: Non-omega-6 enriched formula
Number of subjects: 37

Group type: COMPARATOR
Intervention: Non-omega-3 formula
Number of subjects: 37
Study: 10609213

Group type: EXPERIMENTAL
Intervention: Nesacaine-MPF 3%
Number of subjects: 40

Group type: COMPARATOR
Intervention: Nesacaine-MPF 2%
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Nesacaine-MPF 2% and 3%
Number of subjects: 40
Study: 7589632

Group type: EXPERIMENTAL
Intervention: Goserelin acetate (3.6 mg SC depot formulation once monthly for 6 months) plus estrogen-progestogen add-back therapy (2 mg 17 beta-E2 and 1 mg norethisterone acetate once daily for 6 months)
Number of subjects: 88

Group type: COMPARATOR
Intervention: Goserelin acetate (3.6 mg SC depot formulation once monthly for 6 months)
Number of subjects: 88
Study: 1958438

Group type: EXPERIMENTAL
Intervention: ICI 169,369 (80 mg)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: ICI 169,369 (120 mg)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study: 6752042

Group type: EXPERIMENTAL
Intervention: Thymopoietin pentapeptide (TP-5), treated for 6 weeks
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo treatment, control group
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Thymopoietin pentapeptide (TP-5)
Number of subjects: 0
Study: 31044748

Group type: COMPARATOR
Intervention: Tenofovir disoproxil fumarate (TDF) 300 mg/day
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Tenofovir disoproxil fumarate (TDF) 300 mg/day plus telbivudine (LDT) 600 mg/day
Number of subjects: 70
Study: 28710224

Group type: EXPERIMENTAL
Intervention: 3-month automated closed-loop insulin delivery combined with pump suspend feature
Number of subjects: 84

Group type: COMPARATOR
Intervention: Sensor-augmented insulin pump therapy
Number of subjects: 84
Study: 24962144

Group type: EXPERIMENTAL
Intervention: Monovision correction
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Multifocal intraocular lens (IOL) implantation
Number of subjects: 75

Group type: COMPARATOR
Intervention: Both techniques (Monovision and Multifocal IOL)
Number of subjects: 75
Study: 23406253

Group type: EXPERIMENTAL
Intervention: Topical medications with percentage IOP reduction >22.1%
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: Topical medications with percentage IOP reduction
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: Occurrence of disc haemorrhage
Number of subjects: 121
Study: 21158862

Group type: EXPERIMENTAL
Intervention: Nutrition Detectives™ program
Number of subjects: 1180
Study: 19327906

Group type: EXPERIMENTAL
Intervention: Deodorant
Number of subjects: 84
Study: 18052663

Group type: EXPERIMENTAL
Intervention: Protocolized cognitive-behavioural group therapy
Number of subjects: 57

Group type: COMPARATOR
Intervention: Waiting list control group
Number of subjects: 57
Study: 15821216

Group type: EXPERIMENTAL
Intervention: Bronchoscopic lavage
Number of subjects: 14

Group type: COMPARATOR
Intervention: Nonbronchoscopic lavage
Number of subjects: 14
Study: 11976154

Group type: EXPERIMENTAL
Intervention: LSE + high-intensity physical training
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: LSE + moderate-intensity physical training
Number of subjects: 80

Group type: COMPARATOR
Intervention: LSE + moderate-intensity physical training and LSE + high-intensity physical training (combined)
Number of subjects: 80
Study: 9473913

Group type: EXPERIMENTAL
Intervention: Lithium treatment
Number of subjects: 25

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study: 7613144

Group type: EXPERIMENTAL
Intervention: Oral doses of 0.1 ng nickel sulfate per day, following a low-nickel diet
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Oral provocation tests
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Patch tests
Number of subjects: 51
Study: 2225503

Group type: EXPERIMENTAL
Intervention: Nitrous oxide (Entonox)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Papaveretum
Number of subjects: 0
Study: 373089

Group type: EXPERIMENTAL
Intervention: Cystic fibrosis patients inhaling test aerosol
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Cystic fibrosis patients with terbutaline
Number of subjects: 7

Group type: COMPARATOR
Intervention: Patients with immotile-cilia syndrome
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Coughing during clearance measurements in CF patients
Number of subjects: 7

Group type: COMPARATOR
Intervention: Discomfort from rhinitis, sinusitis, and otitis
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Ciliary ultrastructure in CF patients
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Mucociliary transport rate in CF patients
Number of subjects: 7
Study: 31734699

Group type: EXPERIMENTAL
Intervention: Inactivated EV71 vaccine (2 doses at 1 month interval)
Number of subjects: 155995

Group type: COMPARATOR
Intervention: Control group (no vaccination)
Number of subjects: 155995

Group type: EXPERIMENTAL
Intervention: Inactivated EV71 vaccine
Number of subjects: 155995
Study: 30616740

Group type: EXPERIMENTAL
Intervention: GSTT1 null genotypes with exposure to mother's, father's, or parental tobacco smoke in early life
Number of subjects: 620

Group type: EXPERIMENTAL
Intervention: GSTM1 null genotypes with exposure to father's or parental smoking
Number of subjects: 620

Group type: EXPERIMENTAL
Intervention: GSTP1 Ile/Ile genotypes with exposure to mother's smoking
Number of subjects: 620

Group type: COMPARATOR
Intervention: GSTP1 Val/Val or Ile/Val genotypes with exposure to mother's smoking
Number of subjects: 620
Study: 28389316

Group type: EXPERIMENTAL
Intervention: Vinflunine (320 mg/m2 or 280 mg/m2 every 21 days)
Number of subjects: 88

Group type: COMPARATOR
Intervention: Best supportive care
Number of subjects: 88
Study: 25527052

Group type: EXPERIMENTAL
Intervention: Endoscopic nasogallbladder drainage (ENGBD) using a 5F or 7F tube (n = 37)
Number of subjects: 73

Group type: COMPARATOR
Intervention: Endoscopic gallbladder stenting (EGBS) using a 7F stent (n = 36)
Number of subjects: 73
Study: 23981994

Group type: EXPERIMENTAL
Intervention: Cyberwand dual probe lithotriptor (Group A)
Number of subjects: 138

Group type: COMPARATOR
Intervention: Swiss lithoclast master (Group B)
Number of subjects: 138
Study: 21420121

Group type: EXPERIMENTAL
Intervention: Laser acupuncture therapy performed 3 times a week for 4 weeks
Number of subjects: 91

Group type: COMPARATOR
Intervention: Placebo group (nonlaser light to the same points)
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: Laser acupuncture therapy
Number of subjects: 91
Study: 18842668

Group type: EXPERIMENTAL
Intervention: Haloperidol (HAL)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Olanzapine (OLZ)
Number of subjects: 36
Study: 17272326

Group type: EXPERIMENTAL
Intervention: DDD(R)/VDD pacing
Number of subjects: 41

Group type: COMPARATOR
Intervention: VVI(R) pacing
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Functional class assessment
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Presence of pacemaker syndrome
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Patients' preferred pacing mode
Number of subjects: 41
Study: 15577366

Group type: EXPERIMENTAL
Intervention: Surgical repair of split earlobes
Number of subjects: 25

Group type: COMPARATOR
Intervention: Heavy gold earrings (stretched earlobes)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Gold earrings (normal earlobes)
Number of subjects: 25
Study: 11605920

Group type: EXPERIMENTAL
Intervention: Intravenous fentanyl (10 microg/kg estimated fetal weight x 1.25 placental correction) given once at intrahepatic vein transfusion
Number of subjects: 16

Group type: COMPARATOR
Intervention: Control transfusions without fentanyl
Number of subjects: 16

Group type: COMPARATOR
Intervention: Intrahepatic vein transfusions without fentanyl
Number of subjects: 16
Study: 9232713

Group type: EXPERIMENTAL
Intervention: Postal invitations to influenza vaccination free of charge
Number of subjects: 585

Group type: EXPERIMENTAL
Intervention: Postal invitations to influenza vaccination on paying the usual fee (US$ 40‐60)
Number of subjects: 585

Group type: COMPARATOR
Intervention: Control group (vaccinated at their own request and paying the usual fee)
Number of subjects: 585
Study: 7955811

Group type: EXPERIMENTAL
Intervention: Lomefloxacin with sucralfate (1 gm)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Lomefloxacin with ferrous sulfate (100 mg elemental iron)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Lomefloxacin with calcium carbonate (500 mg calcium)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Lomefloxacin with milk (300 ml)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Lomefloxacin alone
Number of subjects: 8
Study: 3311119

Group type: EXPERIMENTAL
Intervention: Ceftazidime
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Gentamicin and Carbenicillin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Saline
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Antibiotic regimen
Number of subjects: 0
Study: 31565912

Group type: EXPERIMENTAL
Intervention: Whey protein isolate
Number of subjects: 8

Group type: COMPARATOR
Intervention: Isocaloric placebo
Number of subjects: 8
Study: 29947919

Group type: EXPERIMENTAL
Intervention: CHIR-Net hospitals
Number of subjects: 475

Group type: COMPARATOR
Intervention: Non-CHIR-Net hospitals
Number of subjects: 475
Study: 28494974

Group type: EXPERIMENTAL
Intervention: CRT with defibrillator (CRT-D)
Number of subjects: 1214

Group type: COMPARATOR
Intervention: ICD alone
Number of subjects: 1214

Group type: EXPERIMENTAL
Intervention: CRT-D
Number of subjects: 1214
Study: 25615445

Group type: EXPERIMENTAL
Intervention: Tadalafil 5 mg once daily
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 22883561

Group type: EXPERIMENTAL
Intervention: Primary split-thickness skin grafting after excision of carbuncle
Number of subjects: 0
Study: 20871416

Group type: COMPARATOR
Intervention: Group-C: fortnightly follow-up at community-based follow-up units, including growth monitoring and promotion, health education, and micronutrient supplementation (n = 17)
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: Group-SF: same as group-C plus supplementary food (150 to 300 kcal/day) (n = 23)
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: Group-PS: same as group-C plus psychosocial stimulation (n = 17)
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: Group-SF + PS: same as group-C plus SF and PS (n = 20)
Number of subjects: 77

Group type: COMPARATOR
Intervention: Nonmalnourished children (comparison group) (n = 17)
Number of subjects: 77
Study: 18266048

Group type: EXPERIMENTAL
Intervention: (32)P
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control (no (32)P)
Number of subjects: 30
Study: 16901593

Group type: EXPERIMENTAL
Intervention: Invivac (Solvay Pharmaceuticals)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Fluad (Chiron)
Number of subjects: 0
Study: 12749757

Group type: EXPERIMENTAL
Intervention: Glatiramer acetate 20 mg/day
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 10908933

Group type: EXPERIMENTAL
Intervention: Autograft
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Allograft
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Xenograft
Number of subjects: 43

Group type: COMPARATOR
Intervention: All groups
Number of subjects: 43
Study: 9173649

Group type: EXPERIMENTAL
Intervention: Patients with internal endometriosis
Number of subjects: 16

Group type: COMPARATOR
Intervention: Control group (20 healthy women)
Number of subjects: 16
Study: 1601605

Group type: EXPERIMENTAL
Intervention: Shockwave lithotripsy with ethyl propionate
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Shockwave lithotripsy with isopropyl acetate
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Shockwave lithotripsy with 70%:30% MTBE/DMSO mixture
Number of subjects: 0

Group type: COMPARATOR
Intervention: Bile (control)
Number of subjects: 0
Study: 6423063

Group type: EXPERIMENTAL
Intervention: Oestrogen treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 30321833

Group type: EXPERIMENTAL
Intervention: High-flow nasal therapy (HFNT)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Standard oxygen (SO)
Number of subjects: 54
Study: 27049176

Group type: EXPERIMENTAL
Intervention: Theophylline
Number of subjects: 60

Group type: COMPARATOR
Intervention: Standard treatment (no theophylline)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 60
Study: 24755136

Group type: EXPERIMENTAL
Intervention: Lorazepam 1 mg before sleep with noise exposure
Number of subjects: 8

Group type: COMPARATOR
Intervention: Control (Lorazepam 1 mg before sleep without noise exposure)
Number of subjects: 8
Study: 22377540

Group type: EXPERIMENTAL
Intervention: Oxytocin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Arginine vasopressin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 20350990

Group type: EXPERIMENTAL
Intervention: High-concentration oxygen (40% and high concentration via Hudson non-rebreathing mask)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Medical air
Number of subjects: 13
Study: 18331216

Group type: EXPERIMENTAL
Intervention: Calcium carbasalate (380 mg/day)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Acetazolamide (500 mg/day)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Calcium carbasalate and placebo (pooled)
Number of subjects: 15
Study: 16341372

Group type: EXPERIMENTAL
Intervention: Theophylline (250 mg) administered twice a day for 15 days in addition to inhaled salbutamol and ipratropium bromide
Number of subjects: 38

Group type: COMPARATOR
Intervention: Placebo administered twice a day for 15 days in addition to inhaled salbutamol and ipratropium bromide
Number of subjects: 38
Study: 12763518

Group type: EXPERIMENTAL
Intervention: Hormone replacement therapy (HRT)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Oral oestrogen alone
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Oral oestrogen combined with progestin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Transdermal HRT
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Raloxifene
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Tamoxifen
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Low-dose HRT
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Tibolone
Number of subjects: 0
Study: 10872714

Group type: EXPERIMENTAL
Intervention: Tape recordings for home use for one week
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control group (no tape recordings)
Number of subjects: 50
Study: 8622076

Group type: COMPARATOR
Intervention: CMFVP (Cyclophosphamide, Methotrexate, Fluorouracil, Vincristine, and Prednisone)
Number of subjects: 945

Group type: EXPERIMENTAL
Intervention: VATH (Vinblastine, Doxorubicin, Thiotepa, and Halotestin)
Number of subjects: 945

Group type: EXPERIMENTAL
Intervention: VATH
Number of subjects: 945
Study: 1289923

Group type: EXPERIMENTAL
Intervention: S-adenosyl-L-methionine (SAMe) 200 mg/day intramuscularly
Number of subjects: 63

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 63
Study: 6377145

Group type: EXPERIMENTAL
Intervention: Low-dose prostaglandin E2 vaginal gel
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 31245006

Group type: EXPERIMENTAL
Intervention: High-dose behavioral treatment (24 sessions)
Number of subjects: 287

Group type: EXPERIMENTAL
Intervention: Moderate-dose behavioral treatment (16 sessions)
Number of subjects: 287

Group type: EXPERIMENTAL
Intervention: Low-dose behavioral treatment (8 sessions)
Number of subjects: 287

Group type: COMPARATOR
Intervention: Control group (nutrition education, 8 sessions)
Number of subjects: 287
Study: 29986700

Group type: EXPERIMENTAL
Intervention: Genotype-guided dosing
Number of subjects: 322

Group type: COMPARATOR
Intervention: Traditional dosing
Number of subjects: 322
Study: 27473269

Group type: EXPERIMENTAL
Intervention: Melatonin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 24657555

Group type: EXPERIMENTAL
Intervention: Functionally orientated treatment based on the SDA concept
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventional treatment using RPDs
Number of subjects: 0
Study: 22980305

Group type: EXPERIMENTAL
Intervention: Edifoligide
Number of subjects: 3014

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3014
Study: 19395186

Group type: EXPERIMENTAL
Intervention: RT+AST (radiation plus 6 months of androgen suppression therapy)
Number of subjects: 206

Group type: COMPARATOR
Intervention: RT (radiation therapy)
Number of subjects: 206
Study: 17319791

Group type: EXPERIMENTAL
Intervention: Anthracycline therapy (PA)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Different antitumor drugs (P0)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Control group (C)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Baroreflex sensitivity (BRS)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Inter-beat interval (IBI)
Number of subjects: 31
Study: 11004860

Group type: EXPERIMENTAL
Intervention: Smokers (n=1726)
Number of subjects: 3004

Group type: COMPARATOR
Intervention: Non-smokers (n=1278)
Number of subjects: 3004
Study: 9095608

Group type: EXPERIMENTAL
Intervention: Bupivacaine and fentanyl (group E)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Intravenous fentanyl and bupivacaine (group I)
Number of subjects: 75

Group type: COMPARATOR
Intervention: Bupivacaine alone (group C)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Intravenous fentanyl (group I)
Number of subjects: 75
Study: 8455424

Group type: EXPERIMENTAL
Intervention: Interferon alfa (3 million units, three times weekly)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Prednisolone withdrawal followed by interferon alfa (3 million units, three times weekly)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Spontaneous normalization without treatment
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Prednisolone pretreatment followed by interferon therapy
Number of subjects: 48

Group type: COMPARATOR
Intervention: No prednisolone pretreatment followed by interferon therapy
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Patients with rebound after prednisolone withdrawal
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Clinical relapse after therapy
Number of subjects: 48
Study: 3094355

Group type: EXPERIMENTAL
Intervention: Nicardipine (30 or 40 mg 3 times daily)
Number of subjects: 63

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 63
Study: 27995728

Group type: EXPERIMENTAL
Intervention: Thiel-embalmed cadavers (T)
Number of subjects: 282

Group type: COMPARATOR
Intervention: Mannequins only (NT)
Number of subjects: 282
Study: 27507236

Group type: EXPERIMENTAL
Intervention: Whey protein supplementation (20 g) with heavy progressive resistance training
Number of subjects: 205

Group type: EXPERIMENTAL
Intervention: Whey protein supplementation (20 g) with light load training
Number of subjects: 205

Group type: EXPERIMENTAL
Intervention: Collagen protein supplementation (20 g) with heavy progressive resistance training
Number of subjects: 205

Group type: EXPERIMENTAL
Intervention: Collagen protein supplementation (20 g) with light load training
Number of subjects: 205

Group type: EXPERIMENTAL
Intervention: Carbohydrates supplementation (20 g) with heavy progressive resistance training
Number of subjects: 205

Group type: EXPERIMENTAL
Intervention: Carbohydrates supplementation (20 g) with light load training
Number of subjects: 205

Group type: EXPERIMENTAL
Intervention: Whey protein supplementation (20 g)
Number of subjects: 205